Skip to content
Search

Latest Stories

Contractors can now order Covid-19 lateral flow antigen testing kits

All community pharmacy contractors can now order Covid-19 lateral flow testing - a tool to detect large numbers of individuals with infections in a rapid and timely.

In a bid to limit transmission, the new rapid testing will be made available to all asymptomatic patient-facing community pharmacy members of staff.


NHS officials have written to contractors with information on the necessary arrangements that need be put in place in order to to roll out the testing in community pharmacy settings.

The guideline also includes further information on how to order and receive deliveries of lateral flow antigen testing kits for pharmacy staff.

Process of ordering

  • Primary Care Services England (PCSE) has started to invite primary care contractors to order lateral flow testing devices
  • contractors have been advised not to place orders until they have received this invitation
  • following receipt of an invitation, organisations should log on and complete their order as quickly as possible. The final closing date for orders across all contractors will be December 30
  • contractors will be asked to order one box for every patient-facing employee delivering NHS services. This should include any temporary patient-facing staff who provide NHS services through the contractor
  • delivery for most contractors that have placed orders is expected to start from early January
  • contractors should distribute one box to each member of patient-facing staff as soon as possible after delivery. Each box will contain 25 lateral flow tests, enough for 12 weeks.

“Anyone who tests positive with a lateral flow antigen test will be required to follow government guidelines, self-isolate with their household and get a confirmatory PCR test,” NHS has said in its letter to all community pharmacy contractors.

“…It is a statutory requirement to report all results, including negative, positive or void. This platform will be available from the end of this week,” the letter added.

Commenting on the latest testing initiative, Claire Anderson, chair of the RPS English Pharmacy Board, said: “We very much welcome the allocation of lateral flow tests to help protect pharmacy teams. Being able to test regularly is a step forward in uncovering more cases, but is not the answer on its own.

“It’s important that teams still follow social distancing guidance, washing hands and other infection control processes where at all possible to also help reduce spread of the virus. I urge community pharmacies to sign up and order as soon as possible.”

The supply of these tests will allow all patient-facing staff to be able to test twice-weekly, using self-administered nasal swabbing and report their results through an online platform.

Any positive lateral flow antigen tests will need to be followed up by a confirmatory PCR test.

One of the major objectives of the latest testing process is to improve virus detection in primary care thereby helping to protect staff, reduce transmission and improve the resilience of services.

The latest move for Covid-19 lateral flow antigen test follows the government’s announcement in November that a lateral flow testing facility would be made available to all asymptomatic patient-facing NHS staff.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less